U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30ClN7O4S
Molecular Weight 548.058
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDOXABAN

SMILES

CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C3=NC4=C(CN(C)CC4)S3

InChI

InChIKey=HGVDHZBSSITLCT-JLJPHGGASA-N
InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1

HIDE SMILES / InChI

Description

Edoxaban (DU-176b, trade names Savaysa, Lixiana) is a selective factor Xa inhibitor reduces thrombin generation and thrombus formation and is an orally bioavailable anticoagulant drug. It was developed by Daiichi Sankyo to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis and pulmonary embolism following 5-10 days of initial therapy with a parenteral anticoagulant.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.561 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
SAVAYSA
Primary
SAVAYSA
Primary
SAVAYSA

Cmax

ValueDoseCo-administeredAnalytePopulation
305 ng/mL
60 mg 2 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
507 ng/mL
90 mg 1 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
649 ng/mL
120 mg 1 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
302 ng/mL
60 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
312 ng/mL
60 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
33.5 ng/mL
10 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
375 ng/mL
90 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
409 ng/mL
120 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
487 ng/mL
150 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
152 ng/mL
30 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1805 ng × h/mL
60 mg 2 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
2806 ng × h/mL
90 mg 1 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
3682 ng × h/mL
120 mg 1 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
1779 ng × h/mL
60 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
1781 ng × h/mL
60 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
259 ng × h/mL
10 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
2680 ng × h/mL
90 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
2789 ng × h/mL
120 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
4322 ng × h/mL
150 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
993 ng × h/mL
30 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
9.44 h
60 mg 2 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
9.2 h
90 mg 1 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
9.75 h
120 mg 1 times / day multiple, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
8.9 h
60 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
9.75 h
60 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
5.79 h
10 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
9.3 h
90 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
8.56 h
120 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
10.7 h
150 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens
8.92 h
30 mg single, oral
EDOXABAN TOSYLATE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
45%
unknown, unknown
EDOXABAN TOSYLATE plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Nonvalvular Atrial Fibrillation: 60 mg taken orally once daily Deep Vein Thrombosis and Pulmonary Embolism: 60 mg taken orally once daily following 5 to 10 days of initial therapy with a parenteral anticoagulant. If a dose of is missed, the dose should be taken as soon as possible on the same day. Dosing should resume the next day according to the normal dosing schedule. The dose should not be doubled to make up for a missed dose.
Route of Administration: Oral
In Vitro Use Guide
In vitro, FXa inhibition, specificity and anticoagulant activities were examined. DU-176b (Edoxaban) inhibited FXa with Ki values of 0.561 nm for free FXa, 2.98 nm for prothrombinase, and exhibited >10 000-fold selectivity for FXa. In human plasma, DU-176b doubled prothrombin time and activated partial thromboplastin time at concentrations of 0.256 and 0.508 microm, respectively.